loading page

Eltrombopag Dose Adjustment During Reactive Secondary Thrombocytosis in patient with ITP
  • +1
  • Mohanad Ahmed,
  • Elabbass Abdelmahmuod,
  • mohamed yassin,
  • Elrazi Ali
Mohanad Ahmed
Author Profile
Elabbass Abdelmahmuod
Author Profile
mohamed yassin
HMC NCCCR
Author Profile
Elrazi Ali
Author Profile

Abstract

Eltrombopag is relatively new drug used in Thrombocytopenia. Its dose should be adjusted based on platelets count. It should be stopped when platelets count reach 400,000/mm³. Here, we share our case report of stopping Eltrombopag based on platelets increment in secondary reactive thrombocytosis irrespective of Eltrombopag treatment.